Epilepsy Research

YKP3089C021: An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures
Sponsor: SK Life Science Inc.
Phase of Development: Phase III
Study Duration: 12 week titration phase followed by an open label maintenance phase until study drug approval
Enrollment Status: Closed
Principal Investigator:  Joanne B. Rogin, MD

A0081096: A Prospective, Randomized, 12-week, Controlled Study of Visual Field Change in Subjects with Partial Seizures Receiving Pregabalin or Placebo
Sponsor: Pfizer, Inc.
Phase of Development: Phase IV
Study Duration: 15 weeks
Enrollment Status: Open
Principal Investigator:  Joanne B. Rogin, MD

SP0982: A double-blind, randomized, placebo-controlled, parallel-group, adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy.
Sponsor: UCB Biosciences, Inc.
Phase of Development: Phase III
Study Duration: 36 weeks
Enrollment Status: Closed
Principal Investigator:  Joanne B. Rogin, MD

EP0012: An open-label, multicenter extension study to evaluate the long-term safety and efficacy of lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy.
Sponsor: UCB Biosciences, Inc.
Phase of Development: Phase III
Study Duration: 5 years
Enrollment Status: Closed
Principal Investigator:  Joanne B. Rogin, MD

SEP093-701: Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Patients with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Phase IV Trial
Sponsor: Sunovion Pharmaceuticals Inc.
Phase of Development: Phase IV
Study Duration: 31 weeks
Enrollment Status: Closed
Principal Investigator:  Joanne B. Rogin, MD

E2007-G000-410: Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First
Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized
Seizures or With Primary Generalized Tonic-Clonic Seizures
Sponsor: Eisai Inc.
Phase of Development: Phase 4
Study Duration: 56 Weeks
Enrollment Status: Open
Principal Investigator:  Joanne B. Rogin, MD

YKP 3089 CO25: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Cenobamate Adjunctive Therapy in subjects with primary generalized tonic-clonic seizures.
Sponsor: SK Life Sciences
Phase of Development: III
Study Duration: 25 weeks
Enrollment: Open
Principal Investigator:  Joanne B. Rogin, MD

XPF-008-201: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy
Sponsor: Xenon
Phase of Development: II
Study duration: 12 weeks
Enrollment: Open
Principal Investigator:  Joanne B. Rogin, MD

EP0092: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY
Sponsor: UCB
Phase of Development: III
Study Duration: 23 Weeks
Enrollment: Open
Principal Investigator:  Joanne B. Rogin, MD

Important Information:
A description of all the clinical trials stated above are available on https://clinicaltrials.gov/, as required by U.S. Law.

All epilepsy clinical trials being conducted at the Minneapolis Clinic of Neurology are approved by an independent ethics committee called an Institutional Review Board (IRB).  An IRB is a type of committee used in research in the United States that has been formally designated to approve, monitor, and review biomedical and behavioral research involving human subjects.  The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of human subjects participating in a research study.